Horizon Discovery is creating human isogenic cell lines aimed at making drug discovery faster and more effective, potentially leading to the creation of more targeted or personalized medicines. Their virus-based technique, known as GENESIS, can precisely engineer disease-causing and patient-specific single, double, and triple genetic mutations into normal human cells. GENESIS underpins Horizon's rapidly growing portfolio of X-MAN (Mutant And Normal) cell-line pairs that may help pharmaceutical researchers assess the likely patient response to a potential drug candidate by defining the potential patient responder demographic much earlier in the development time line.
Headquarters
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.
Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs
With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
First-quarter results season featured tariff talk but without any full-year quantitation. As tariffs and foreign exchange movements bump up against capped drug prices, profitability could suffer.
